Company / Net Income
Vanda Pharmaceuticals Inc. Net Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
$2.5M
FY2025
5-year range
$2.5M / $115.6M
FY2021-FY2025
Trend
-60.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Net Income has fluctuated over the past 10 years, ranging from -$40M in FY2017 to $116M in FY2021.
Based on SEC 10-K filings.
$3M in FY2025 with a 5-year CAGR of -37.0%.
Declined from $33M to $3M over the past 2 years.
Net Income over time
Growth rates
- 3-Year CAGR
- -52.4%
- 5-Year CAGR
- -37.0%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -37.0%, indicating a declining trend.
- In FY2025, net income decreased 60.0% year-over-year.
- Peak net income was recorded in FY2021.
- Lowest net income in the period was in FY2017.
Company context
Key Data Points
- Altman Z-Score -3.96 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.5M | -60.0% |
| FY2024 | $6.3M | -81.1% |
| FY2023 | $33.2M | +42.1% |
| FY2022 | $23.3M | -79.8% |
| FY2021 | $115.6M | +358.4% |
| FY2020 | $25.2M | +261.9% |
| FY2019 | -$15.6M | +13.6% |
| FY2018 | -$18.0M | +54.8% |
| FY2017 | -$39.9M | -297.5% |
| FY2016 | $20.2M | +195.9% |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026